Systemic inflammation and B cell indices predict rituximab responses in membranous nephropathy.
Аннотация
BACKGROUND
Membranous nephropathy (MN) is a frequent cause of nephrotic syndrome in adults with variable response to rituximab (RTX) therapy. While traditional markers like proteinuria and anti-phospholipase A2 receptor (PLA2R) antibodies exhibit predictive value, their limitations necessitate more robust biomarkers.
METHODS
We prospectively analysed 149 MN patients receiving RTX over 12 months. Inflammatory indices such as neutrophil:lymphocyte ratio (NLR), monocyte:lymphocyte ratio (MLR) and systemic inflammation response index (SIRI) together with B cell levels were measured alongside conventional markers at baseline, 3 months and 6 months. Predictive models for 6- and 12-month remission (complete/partial) were developed using multivariate regression and receiver operating characteristics (ROC) analysis.
RESULTS
Non-responders exhibited persistently elevated inflammatory markers (NLR, MLR, SIRI) throughout the entire observation period. Among the three, only SIRI can independently predict the remission of MN. At 3 months, SIRI ≤1.25 {odds ratio [OR] 3.68 [95% confidence interval (CI) 1.39-9.72]} and B cell proportion ≤0.2% [OR 2.90 (95% CI 1.00-8.35)] independently predicted 6-month response. Incorporating these two newly added indicators into the traditional variable model, which includes the levels of proteinuria, albumin and anti-PLA2R antibody at 3 months, markedly enhances prediction accuracy [area under the curve (AUC) 0.86 versus 0.81]. By 6 months, only SIRI ≤0.9 [OR 4.84 (95% CI 1.43-16.40)] and albumin change [OR 1.11 (95% CI 1.03-1.19)] predicted 12-month prognosis, as B cell and anti-PLA2R antibody levels lost significance. The prediction model incorporating SIRI also had better performance (AUC 0.82 versus 0.79).
CONCLUSIONS
B lymphocyte levels constitute a robust predictive biomarker for assessing short-term therapeutic response in patients with MN receiving RTX therapy. Furthermore, SIRI emerges as a valuable prognostic indicator capable of predicting both short-term efficacy and long-term renal outcomes. These findings suggest that concurrent monitoring of B lymphocyte levels and SIRI values warrants integration into standardized monitoring frameworks within clinical management protocols.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.